Eli Lilly (LLY) has built $1.5B worth of pre-launch inventory of orforglipron, the company’s experimental oral weight-loss drug, ahead of the U.S. Food and Drug Administration’s expected decision in April, Reuters reports.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly Stock (LLY) Gets New ‘Buy Rating’ After Strong Earnings
- Fisher Asset Management Boosts Eli Lilly Stake by 153K Shares
- XLV, VHT, IXJ: Gain Exposure to the Entire Healthcare Sector with These ETFs
- Eli Lilly upgraded to Buy from Hold at Freedom Capital
- Lilly Advances Eloralintide Into Phase 3, Expanding Its Obesity Drug Ambitions